Mylan partners with Revance to develop Botox biosimilar

This article was originally published here

Mylan has entered into a global collaboration and license agreement with Revance Therapeutics to develop and commercialize a proposed biosimilar to Botox (onabotulinumtoxinA).

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply